Boston Partners
AVDL

Boston Partners’s Avadel Pharmaceuticals AVDL Stock Holding History

Boston Partners’s Portfolio AVDL Stock Details AVDL Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2018
Q1 		– Sell
-177,951
Closed -$1.46M – 734
2017
Q4 		$1.46M Hold
177,951
– – ﹤0.01% 695
2017
Q3 		$1.87M Buy
+177,951
New +$1.7M ﹤0.01% 678

Other funds holding AVDL

BIP
Brandes Investment Partners La Jolla, California $14.3B AUM 23.11% 1-Year Est. Return
DM
Deerfield Management New York $8.48B AUM 99.04% 1-Year Est. Return
BC
Broadfin Capital New York $747M AUM 100.56% 1-Year Est. Return
AC
Armistice Capital New York $8.17B AUM 68.82% 1-Year Est. Return
Acadian Asset Management
Acadian Asset Management Boston, Massachusetts $84.2B AUM 55.88% 1-Year Est. Return
PA
Perceptive Advisors New York $5.12B AUM 314.02% 1-Year Est. Return
Deutsche Bank
Deutsche Bank Frankfurt Am Main Ge, Germany $344B AUM 42.99% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return
BCM
Brown Capital Management Baltimore, Maryland $500M AUM 25.3% 1-Year Est. Return
GTC
Ghost Tree Capital New York $331M AUM 70.11% 1-Year Est. Return

Boston Partners's AVDL Position: Q1 2018 in Review

Boston Partners sold out of Avadel Pharmaceuticals (AVDL) in Q1 2018, closing a stake of 177,951 shares — an estimated $1.46M sold.

Boston Partners first reported a position in AVDL in Q3 2017 and held it in 2 quarters. The position peaked at $1.87M in Q3 2017. 80 funds tracked by Wall St. Rank hold AVDL as of Q1 2018.

  • Boston Partners reported no remaining Avadel Pharmaceuticals position as of Q1 2018 after selling out during the quarter.
  • Boston Partners sold 177,951 Avadel Pharmaceuticals shares in Q1 2018, an estimated $1.46M.
  • Boston Partners first reported a position in Avadel Pharmaceuticals in Q3 2017 and held it in 2 quarters.
  • Boston Partners's Avadel Pharmaceuticals position peaked at $1.87M in Q3 2017.
  • 80 funds tracked by Wall St. Rank held Avadel Pharmaceuticals as of Q1 2018.

Based on Boston Partners's 13F filing for Q1 2018, filed 4 May 2018.